{"id":576315,"date":"2021-12-23T00:00:00","date_gmt":"2021-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0008-2021-biopharma-angelmans-syndrome-executive-insights-us-eu5-china-2021\/"},"modified":"2026-03-31T10:41:33","modified_gmt":"2026-03-31T10:41:33","slug":"exincg0008-2021-biopharma-angelmans-syndrome-executive-insights-us-eu5-china-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0008-2021-biopharma-angelmans-syndrome-executive-insights-us-eu5-china-2021\/","title":{"rendered":"Angelman&#8217;s Syndrome | Executive Insights | US\/EU5\/China | 2021"},"content":{"rendered":"<p>Clarivate publishes content on Angelman syndrome and its current and future management, patient journey, and the competitive landscape in the U.S., EU5, and China markets between 2021 and 2031<\/p>\n","protected":false},"template":"","class_list":["post-576315","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-china","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576315\/revisions"}],"predecessor-version":[{"id":577554,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576315\/revisions\/577554"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}